Survival outcomes after rituximab monotherapy in SMZL patients. (A) OS, LSS, and FFP for the total population of the 108 SMZL patients. (B) FFP according to Maintenance. (C) FFP according to 1 or 2 years maintenance. PFS, progression-free survival; pts, patients.